Skip to main content
Clinical Trials/NL-OMON45131
NL-OMON45131CompletedNot Applicable

A prospective randomized multicentre efficacy study on defining the optimal cryoballoon duration therapy for treatment of atrial fibrillation: The 1-2-3 study - The 1-2-3 study

Medisch Spectrum Twente0 sites222 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
222

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • * Paroxysmal atrial fibrillation eligible for PVI according to current international guidelines.
  • * Age < 75 years.
  • * Willing and able to sign informed consent.
  • * Willing to and capable of following the requested study procedures.

Exclusion Criteria

  • * Age < 18 years.
  • * Pregnancy
  • * Life or follow-up expectancy < 12 months.
  • * Previous PVI.
  • * Contrast allergy.
  • * Creatin clearance level < 60.
  • * LVEF < 40%
  • * Abnormal left atrium anatomy defined as number of PV*s * 2 per side or LA diameter >50mm (measured in the parasternal long axis, as assessed with transthoracic echocardiography) or >40cc/m2. This will lead to exclusion after inclusion but before randomisation.

Investigators

Similar Trials

A prospective randomized multicentre... | Clinical Trial